The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ACCELERATE DIAGNOSTICS | COM | 00430H102 | 2,264 | 100,600 | SH | SOLE | 100,600 | 0 | 0 | ||
| ADAMAS PHARMACEUTICALS INC | COM | 00548A106 | 4,460 | 255,000 | SH | SOLE | 255,000 | 0 | 0 | ||
| AGIOS PHARMACEUTICALS INC | COM | 00847X104 | 8,487 | 90,000 | SH | SOLE | 90,000 | 0 | 0 | ||
| AMAG PHARMACEUTICALS INC | COM | 00163U106 | 10,385 | 190,000 | SH | SOLE | 190,000 | 0 | 0 | ||
| AMARIN CORP PLC | SPONSORED ADR NEW | 023111206 | 4,104 | 1,754,000 | SH | SOLE | 1,754,000 | 0 | 0 | ||
| ARIAD PHARMACEUTICALS INC | COM | 04033A100 | 12,360 | 1,500,000 | SH | SOLE | 1,500,000 | 0 | 0 | ||
| AXOGEN INC | COM | 05463X106 | 3,451 | 985,900 | SH | SOLE | 985,900 | 0 | 0 | ||
| BIODELIVERY SCIENCES INTL IN | COM | 09060J106 | 1,475 | 140,500 | SH | SOLE | 140,500 | 0 | 0 | ||
| BIOLINERX LTD | SPONSORED ADR | 09071M106 | 528 | 250,000 | SH | SOLE | 250,000 | 0 | 0 | ||
| CARA THERAPEUTICS INC | COM | 140755109 | 3,166 | 315,000 | SH | SOLE | 315,000 | 0 | 0 | ||
| CELGENE CORP | RIGHT 12/31/2030 | 151020112 | 1,455 | 490,000 | SH | SOLE | 490,000 | 0 | 0 | ||
| CEMPRA INC | COM | 15130J109 | 17,155 | 500,000 | SH | SOLE | 500,000 | 0 | 0 | ||
| CHIMERIX INC | COM | 16934W106 | 21,295 | 565,000 | SH | SOLE | 565,000 | 0 | 0 | ||
| CLOVIS ONCOLOGY INC | COM | 189464100 | 10,392 | 140,000 | SH | SOLE | 140,000 | 0 | 0 | ||
| CODEXIS INC | COM | 192005106 | 7,861 | 1,724,000 | SH | SOLE | 1,724,000 | 0 | 0 | ||
| EVOKE PHARMA INC | COM | 30049G104 | 1,727 | 245,000 | SH | SOLE | 245,000 | 0 | 0 | ||
| FIBROGEN INC | COM | 31572Q808 | 6,004 | 191,338 | SH | SOLE | 191,338 | 0 | 0 | ||
| FLAMEL TECHNOLOGIES SA | SPONSORED ADR | 338488109 | 5,394 | 300,000 | SH | SOLE | 300,000 | 0 | 0 | ||
| GERON CORP | COM | 374163103 | 6,880 | 1,825,000 | SH | SOLE | 1,825,000 | 0 | 0 | ||
| IMPRIMIS PHARMACEUTICALS INC | COM NEW | 45323A201 | 5,490 | 687,100 | SH | SOLE | 687,100 | 0 | 0 | ||
| INSPIREMD INC | COM NEW | 45779A309 | 400 | 1,250,000 | SH | SOLE | 1,250,000 | 0 | 0 | ||
| INSYS THERAPEUTICS INC NEW | COM NEW | 45824V209 | 6,394 | 110,000 | SH | SOLE | 110,000 | 0 | 0 | ||
| KITE PHARMA INC | COM | 49803L109 | 4,384 | 76,000 | SH | SOLE | 76,000 | 0 | 0 | ||
| LION BIOTECHNOLOGIES INC | COM | 53619R102 | 2,422 | 200,000 | SH | SOLE | 200,000 | 0 | 0 | ||
| MACROGENICS INC | COM | 556099109 | 1,569 | 50,000 | SH | SOLE | 50,000 | 0 | 0 | ||
| MEDGENICS INC | COM NEW | 58436Q203 | 6,851 | 850,000 | SH | SOLE | 850,000 | 0 | 0 | ||
| MIMEDX GROUP INC | COM | 602496101 | 6,136 | 590,000 | SH | SOLE | 590,000 | 0 | 0 | ||
| NEUROCRINE BIOSCIENCES INC | COM | 64125C109 | 5,758 | 145,000 | SH | SOLE | 145,000 | 0 | 0 | ||
| OPHTHOTECH CORP | COM | 683745103 | 4,886 | 105,000 | SH | SOLE | 105,000 | 0 | 0 | ||
| RETROPHIN INC | COM | 761299106 | 11,980 | 500,000 | SH | SOLE | 500,000 | 0 | 0 | ||
| SUPERNUS PHARMACEUTICALS INC | COM | 868459108 | 6,468 | 535,000 | SH | SOLE | 535,000 | 0 | 0 | ||
| TENAX THERAPEUTICS INC | COM | 88032L100 | 1,976 | 606,200 | SH | SOLE | 606,200 | 0 | 0 | ||
| TETRAPHASE PHARMACEUTICALS I | COM | 88165N105 | 6,412 | 175,000 | SH | SOLE | 175,000 | 0 | 0 | ||
| TRACON PHARMACEUTICALS INC | COM | 89237H100 | 171 | 12,172 | SH | SOLE | 12,172 | 0 | 0 | ||
| TRILLIUM THERAPEUTICS INC | COM NEW | 89620X506 | 5,260 | 260,000 | SH | SOLE | 260,000 | 0 | 0 | ||
| ULTRAGENYX PHARMACEUTICAL IN | COM | 90400D108 | 6,830 | 110,000 | SH | SOLE | 110,000 | 0 | 0 | ||
| ZS PHARMA INC | COM | 98979G105 | 3,156 | 75,000 | SH | SOLE | 75,000 | 0 | 0 | ||